Management of Atopy with Dupilumab and Omalizumab in CADINS Disease

In conclusion, treatment with dupilumab and omalizumab for severe, refractory atopic disease in patients with CADINS appears to be effective and well tolerated in patients with CADINS with severe atopy.
Source: Journal of Clinical Immunology - Category: Allergy & Immunology Source Type: research